Assessment of Three Inflammatory Markers of Cardiovascular Diseases with a Special Accent on C-Reactive Protein

Assessment of Three Inflammatory Markers of Cardiovascular Diseases with a Special Accent on C-Reactive Protein

Background: Elevated levels of CRP, myoglobin and creatine kinase are always associated with pathological changes and hence their values give useful information for exact diagnosis and therapy. They are helpful in monitoring the inflammatory processes and associated diseases.

Aim: The aim of this study was to determine the usefulness and practical value of application of CRP detection by comparing it with the results obtained for the classical enzymes - markers of myocardial damage, myoglobin and creatine kinase isoenzyme MB (CK-MB) in pts with acute coronary syndrome (ACS), pts with chronic coronary artery disease (CAD) and in healthy individuals.

Material and Methods: Sera were taken from a total of 152 individuals (78.9% males, 21.1% females, mean age 61.87 ± 10.32 years). The subjects were divided in three groups: 63 pts with ACS; 52 pts CAD and a group of 36 conditionally healthy individuals. Analysis of patients' sera for presence of markers for myocardial damage: myoglobin, CK-MB along with determination of CRP level was done on the Immulite system, DPC (Diagnostic Products Corporation), Los Angeles, USA.

Results: Comparison of examined biomarker's values in pts divided according to diagnosis showed statistically significant higher levels in patients with ACS vs. others. As for biomarker's cut-off values, out of all CK-MB ≥5.7 ng/mL was found in 34 (53.1%) pts with ACS with significant difference among the groups in favor of its higher values in pts with ACS (p=0.0001). Out of all, myoglobin ≥25 ng/mL was found in 54 (84.4%) pts with ACS without significant difference among the groups. As for CRP, value of ≥3 mg/L was found in 39 (60.9%) pts with ACS and there was significant difference among the groups in favor of higher values in pts with ACS (p=0.001). There was significant positive correlation among the levels of examined three biomarkers: CK-MB in correlation to myoglobin (r=0.460; p= 0.0001) and to CRP level (r=0.204; p= 0.009), as well as myoglobin to CRP level (r=0.218; p= 0.005).

Conclusion: We could conclude that determination of CRP levels is a valid test for detection of acute coronary artery disease in addition to the classical, standard markers for myocardial damage.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • Biasucci LM. CDC/AHA workshop on markers of inflammation and cardiovascular disease. Application to clinical and public health practice clinical use of inflammatory markers in patients with cardiovascular diseases. A background paper. Circulation. 2004;110:e560-e567.

  • Du Clos TW. Function of C-reactive protein. Ann Med. 2000; 32:274-8.

  • Pearson TA, Mensah GA, Alexander RW, et al. AHA/CDC scientific Statement Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. A statement for health care professionals from the Centres for Disease Control and the American Heart Association. Circ. 2003;107:499-511.

  • Rifai N, Ridker PM. High sensitivity C - reactive protein: A novel and promising marker of coronary heart disease. Clin Chem. 2001;47930;403-11.

  • Lavin F, Kane M, Forde A, Gannon F, Daly K. Comparison of five cardiac markers in the detection of reperfusion after thrombolysis in acute myocardial infarction. British Hear J. 1995;73(5):422-7.

  • Wong SS. Strategic utilization of cardiac markers for the diagnosis of acute myocardial infarction. Ann Clin Lab Sci. 1996;26:301-12.

  • Wu AH, Feng YJ, Contois JH, Pervaiz S. Comparison of myoglobin, creatine kinaze-MB and cardiac troponin I for diagnosis of acute myocardial infarction. Ann Clin Lab Sci. 1996; 26(4):291-300.

  • Apple FS, Preese LM. Creatine kinase-MB: detection of myocardial infarction and monitoring reperfusion. J Clin Immunoassay. 1994;17:24-9.

  • Gibler WB, Lewis LM, Erb RE et al. Early detection of acute myocardial infarction in patients presenting with chest pain and nondiagnostic ECGs; serial CK-MB sampling in the emergency department. ANN Emerg Med. 1990;19:1359-66.

  • Panteghini M. Creatine kinaze MB isoforms. J Clin Immunoassay. 1994;17:30-4;6.

  • Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995;91:2844-50.

  • Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-26.

  • Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid protein in severe unstable angina. N Engl J Med. 1994;331:417-24.

  • de Beer FC, Hind CR, Fox KM, et al. Measurement of serum C-reactive protein concentration in myocardial ischemia and infarction. Br Heart J. 1982;47:239-43.

  • Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol. 1990;65:168-72.

  • Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-9.

  • Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98:731-3.

  • Tillett WS, Francis T Jr. Serological reactions in pneumonia with a non-protein somatic fraction of pneumonococcus. J Exp Med. 1930; 52:561-71.

  • Ley K, Huo Y. VCAM-1 is critical in atherosclerosis. J Clin Invest. 2001;107:1209-10.

  • Lagrand WK, Visser CA, Hermens WT, et al. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation. 1999;100:96-102.

  • Reynolds GD, Vance RP. C-reactive protein immunohistochemical localization in normal and atherosclerotic human aortas. Arch Pathol Lab Med. 1987;111:265-9.

  • Nakagomi A, Freedman SB, Geczy CL. Interferon-gamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: relationship with age, sex, and hormone replacement treatment. Circulation. 2000;101:1785-91.

  • Pasceri V, Chang J, Willerson JT, et al. Modulation of creactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation. 2001;103:2531-4.

  • Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102:2165-8.

  • Chew DP, Bhatt DL, Robbins MA, Penn MS, Schneider JP, Lauer MS, Topol EJ, Ellis SG. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation. 2001;104(9):992-7.


Journal + Issues